非小细胞肺癌靶向治疗药物的疗效及经济性研究综述

目的综述非小细胞肺癌靶向治疗药物的临床疗效及药物经济学评价结果。方法基于非小细胞肺癌的流行病学特征和治疗发展趋势,选取临床应用较多的靶向治疗药物,并检索国内外相关文献,对其治疗非小细胞肺癌的临床疗效和经济性进行综合分析。结果吉非替尼和厄洛替尼是目前针对非小细胞肺癌最受关注的靶向治疗药物。针对不同类型的患者,两者表现出不同的临床疗效,而较少的药物经济学研究显示了其经济性。结论吉非替尼和厄洛替尼的临床疗效和经济性在总体上优于其它治疗方案,但还需更深入的研究。

Review on Effect and Economy Research of Targeted Therapeutic Drugs for Non-small Cell Lung Cancer

Objective Summarize the effect and pharmacoeconomics evaluation of targeted therapeutic drugs for non-small cell lung cancer （NSCLC）. Methods Select targeted therapeutic drugs widely used clinically based on epidemiological features and treatment development trend of NSCLC.The effect and economics of these drugs were comprehensive analysed using literatures published both in the domestic and overseas. Results The targeted therapeutic drugs of most concern for NSCLC were Gefitinib and Erlotinib.For difference kinds of patients,the two drugs showed different clinical effect.The fewer pharmacoeconomics researches demonstrated their economics. Conclusion The clinical effect and economics of Gefitinib and Erlotinib were better than other treatments as a whole.But it still needs deeper researches.